KZE has prepared a broad array of medical, regulatory, and strategic communication products in support of drugs and devices developed for solid tumors and hematologic malignancies. Our experience spans a range of therapeutic approaches including conventional chemotherapeutics, small molecules targeting specific growth factor receptor or cell cycle pathways, antibodies to cancer-specific antigens, immune modulators, vaccines, and cancer diagnostics.
Medical Writing Products
Peer reviewed clinical trial-based manuscripts
Medical Information Letters
Call center responses
Clinical trial study reports, protocols, investigator brochures and patient-directed communications
Five-year publication plan for a small molecule chemotherapeutic agent in development for colon cancer and pancreatic cancer
Publication team management for an immunotherapeutic vaccine in development for breast cancer
Publication Steering Committee management for key opinion leaders authoring Phase III manuscript for an immunotherapeutic vaccine
Two year publication plan and message mapping for small molecule chemotherapeutic in development for solid and hematopoietic tumors
Product positioning analysis for a chemotherapeutic agent in development for treatment of solid tumors
Analysis comparing press release activity, trial activity, and key messages/themes for 6 small molecule targeted cancer therapeutics in development for solid tumors and hematologic malignancies
Critical assessment of a high throughput chemical synthesis and screening technology used to identify new chemotherapeutics with improved toxicity profiles
Bibliography: Sample Publications and Abstracts
A Amin, AZ Dudek, TF Logan, et al. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer, 3: 14 doi:10.1186/s40425-015-0055-3, 2015.
AK Gopal, R. Ramchandren, RB Berryman, et al. Brentuximab Vedotin (SGN-35) Treatment in Relapsed CD30-positive Hodgkin Lymphoma Patients Following Allogeneic Stem Cell Transplant: A Multicenter Case Series. Slide set for European Group for Blood and Marrow Transplantation 37th Annual Meeting
R Chen, AK Gopal, SE Smith, et al. Results from a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. Poster for the American Society of Clinical Oncology (ASCO) Annual Meeting; June 2011.
C Nicolette, D Healey,, I Tcherepanova, et al. Dendritic Cells for Active Immunotherapy: Optimizing Design and Manufacture in Order to Develop Commercially and Clinically Viable Products. Vaccine 25 Suppl 2:B47-60, 2007.
RA Lopez, AB Goodman, M Rhodes, et al. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-omethylnordihydroguaiaretic acid) formulated for systemic administration. Anti-cancer Drugs18(8):933-9, 2007.
SS Murthy, T Shen, A DeRienzo, WC Lee, PC Ferriola, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 19(3):410-6, 2000.
PC Ferriola and W Stewart. Fibronectin organization and expression in mesothelial and mesothelioma cells. Am. J. Physiology 271:804-12, 1996.
PC Ferriola. Autocrine growth factors and the extracellular matrix: key players in the pathogenesis of lung and pleural cell cancers. In: Eighteenth Annual Interdisciplinary Cancer Research Workshop, C Parkanyi and P Politzer P, eds. Cancer Biochem. Biophys. 15: 199-206, 1996.
Everitt, JI, Bermudez, E., Mangum, JB and Ferriola, PC: Malignant mesothelioma: A legacy of asbestos that affects the safety evaluation of synthetic vitreous fibers. CIIT Activities 16(9): 1-6, 1996
MA Bonham, S Brown, AL Boyd, PH Brown, DA Bruckenstein DA, et al.: An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acid Research, 7:1197-1203, 1995.
PC Ferriola and P Nettesheim. Regulation of normal and transformed tracheobronchial epithelial cell proliferation by autocrine growth factors. Critical Reviews in Oncogenesis 5:107-120, 1994.
CA Carter, MM Doherty, R Rusnak, P Nettesheim and PF Ferriola. Alterations in the localization of F-actin, fibronectin, and thrombospondin occur prior to neoplastic transformation in rat tracheal epithelial cells. Exp. Cell Res. 212:141-150, 1994.
T Iwanaga and PC Ferriola. Cellular uptake of phosphorothioate oligodeoxynucleotides is negatively affected by cell density in a transformed airway epithelial cell line. Biochem. Biophys. Res. Comm. 191:1152-57, 1993.
JC Hanvey, NJ Peffer, JE Bisi, SA Thomson, R Cadilla, JA Josey, CF Hassman, A Bonham, KG Au, SG Carter, DA Bruckenstein, AL Boyd, SA Noble and LE Babiss. Antisense and Antigene Properties of Peptide Nucleic Acids. Science, 258:1481-1485, 1992.
PC Ferriola and P Nettesheim. Alterations in growth factor pathways during multistage carcinogenesis of rat tracheal epithelial cells. J. Radiation Research 2:277-287, 1992.
PC Ferriola, AT Robertson, DW Rusnak, et al. Epidermal growth factor dependence and TGFa autocrine growth regulation in primary rat tracheal epithelial cells. J. Cell. Physiology 152:302-309, 1992.
PC Ferriola, HS Earp, R DiAugustine and P Nettesheim. The role of TGFa and its receptor in proliferation of transformed rat tracheal epithelial cells. J. Cell. Physiology 147:166-175, 1991.
PC Ferriola, AT Robertson, R Steigerwalt and P Nettesheim. Abnormalities in growth regulation of transformed rat tracheal epithelial cells. Pathobiology 58:28-36, 1990.
PC Ferriola, C Walker, C., Robertson, et al. Alterations in growth factor requirements and transforming growth factor gene expression in transformed rat tracheal epithelial cells. Molec Carcinogenesis 2(6):336-344, 1989.
PC Ferriola, V Cody, and EM Middleton. Protein kinase C inhibition by plant flavonoids: kinetic mechanisms and structure-activity relationships. Biochemical Pharmacol. 38:1617-1624, 1989.
EM Middleton and PC Ferriola. Effect of flavonoids on PKC: relationship to inhibition of human basophil histamine release. In: Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular and Medicinal Properties, EM Middleton, V Cody and J Harborne, eds., New York: Alan R. Liss, Inc., 1988.
EM Middleton, PC Ferriola and G Drzewiecki. Effect of flavonoids on tumor promoter induced basophil histamine release and protein kinase C. Trans. Amer. Clin. Climatol. Assoc. 100:47-56, 1988.
EM Middleton and PC Ferriola. Effect of flavonoids on protein kinase C: relationship to inhibition of human basophil histamine release. Prog Clin Biol Res 280: 251-66, 1988.